Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LE6F
|
|||
| Former ID |
DNCL003419
|
|||
| Drug Name |
CC-11050
|
|||
| Indication | Cutaneous lupus erythematosus [ICD-11: EB5Z; ICD-10: L80-L99, L93; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H28N2O6S
|
|||
| Canonical SMILES |
CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2CC3=C(C2=O)C(=CC=C3)NC(=O)C4CC4)OC
|
|||
| InChI |
1S/C24H28N2O6S/c1-4-32-21-12-16(10-11-20(21)31-2)19(14-33(3,29)30)26-13-17-6-5-7-18(22(17)24(26)28)25-23(27)15-8-9-15/h5-7,10-12,15,19H,4,8-9,13-14H2,1-3H3,(H,25,27)/t19-/m1/s1
|
|||
| InChIKey |
QDZOBXFRIVOQBR-LJQANCHMSA-N
|
|||
| CAS Number |
CAS 340019-69-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01300208) To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.